Chikungunya -- Worldwide/Unknown
French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA).
The chikungunya vaccine -- VLA1553 -- has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020, respectively.
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus.
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8627648&promed&0
No comments:
Post a Comment